Evidence map›Paper›PMID 38141549›Full record

ReviewEuropean journal of cancer (Oxford, England : 1990)2024

Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.

Marisa Cobanaj, Chiara Corti, Edward C Dee, Lucas McCullum, Laura Boldrini, Ilana Schlam, Sara M Tolaney, Leo A Celi, Giuseppe Curigliano, Carmen Criscitiello

Abstract readReview
In one paragraph

Review in European journal of cancer (Oxford, England : 1990), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marisa CobanajNational Center for Radiation Research in Oncology, OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Chiara CortiBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy. Electronic address: chiara.corti1@unimi.it.
Edward C DeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lucas McCullumDepartment of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Laura BoldriniDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
Ilana SchlamDepartment of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Sara M TolaneyBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Leo A CeliDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Laboratory for Computational Physiology, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Giuseppe CuriglianoDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
Carmen CriscitielloDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Critical Care Informatics: Ethical considerations around the use and sharing of health-related dataR01EB017205 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CELI, LEO ANTHONY G, MARK, ROGER GREENWOOD · 2014 to 2021
$3.8M
NCI NIH HHS P30 CA008748NIBIB NIH HHS R01 EB017205
6 · The paper itself

Abstract

Patient care workflows are highly multimodal and intertwined: the intersection of data outputs provided from different disciplines and in different formats remains one of the main challenges of modern oncology. Artificial Intelligence (AI) has the potential to revolutionize the current clinical practice of oncology owing to advancements in digitalization, database expansion, computational technologies, and algorithmic innovations that facilitate discernment of complex relationships in multimodal data. Within oncology, radiation therapy (RT) represents an increasingly complex working procedure, involving many labor-intensive and operator-dependent tasks. In this context, AI has gained momentum as a powerful tool to standardize treatment performance and reduce inter-observer variability in a time-efficient manner. This review explores the hurdles associated with the development, implementation, and maintenance of AI platforms and highlights current measures in place to address them. In examining AI's role in oncology workflows, we underscore that a thorough and critical consideration of these challenges is the only way to ensure equitable and unbiased care delivery, ultimately serving patients' survival and quality of life.

Indexed as

Artificial IntelligenceNeoplasmsHumansPatient CareQuality of LifeWorkflowArtificial intelligenceBiasDecision supportEquityInclusivityPrecision medicine

Identifiers

PMID38141549
PMCPMC11362966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.